Communiqués Aridis Pharmaceuticals, Inc.

Actions

ARDS

US0403341045

Marché Fermé - OTC Markets Autres places de cotation 21:59:30 15/07/2024			Varia. 5j.	Varia. 1 janv.
0,065 ^USD	+8,25 %		-8,45 %	-7,28 %

24/06	Aridis Pharmaceuticals, Inc. fournit une mise à jour sur les développements récents de l'entreprise	CI
2023	Aridis Pharmaceuticals, Inc. publie ses résultats pour le troisième trimestre et les neuf mois clos le 30 septembre 2023	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Aridis Provides Corporate Update	24/06	AQ
Aridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until January 12, 2024	15/12	AQ
Aridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business Update	03/11	AQ
Aridis Pharmaceuticals : Termination of Material Agreement - Form 8-K	25/08/23	PU
Aridis Pharmaceuticals Announces $2 Million Offering	02/08/23	AQ
CapitalGainsReport Penny Stock Bounce List: EPAZ, ARDS, FRTX, GNPX	24/07/23	AQ
Aridis Pharmaceuticals : Accelaration/Increase of Financial Obligation - Form 8-K	21/07/23	PU
Aridis Receives Agreement from the European Medicines Agency (EMA) on the Clinical Study Design and a Single Confirmatory Phase 3 Study of AR-301	17/07/23	AQ
Aridis’ AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDA’s Qualified Infectious Diseases Product (QIDP) Designation	12/07/23	AQ
Aridis Pharmaceuticals' AR-301 Eligible for Consideration under FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD)	20/06/23	AQ
ARIDIS PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)	09/06/23	AQ
Aridis Pharmaceuticals Announces First Quarter 2023 Financial Results and Business Update	08/06/23	AQ
Aridis Receives Agreement from the FDA on a Single Confirmatory Phase 3 Study of AR-301 and the Clinical Study Design	31/05/23	AQ
Aridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-Q	25/05/23	AQ
ARIDIS PHARMACEUTICALS, INC. : Termination of a Material Definitive Agreement (form 8-K)	09/05/23	AQ
ARIDIS PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits (form 8-K)	01/05/23	AQ
Aridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-K	26/04/23	AQ
ARIDIS PHARMACEUTICALS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	21/04/23	AQ
Aridis Provides Corporate Update	01/04/23	AQ
ARIDIS PHARMACEUTICALS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Change in Directors or Principal Officers (form 8-K)	31/03/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Aridis Pharmaceuticals, Inc.

Actions

ARDS

US0403341045

Communiqués

Filtres